Triomics nabs $22M to bring oncology-specific AI to cancer centers

Triomics raised $22 million in Series B funding led by Battery Ventures, with participation from existing investors.

The company is scaling its oncology-focused AI platform for cancer centers and workflows.

Its tools help automate clinical trial matching, patient summaries, tumor registry reporting, and other admin tasks.

Triomics says major cancer centers are already using the platform, and adoption is growing quickly.